Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial.

CONCLUSIONS: In AGHD patients somapacitan administered once-weekly demonstrated superiority over placebo, and overall treatment effects and safety of somapacitan were in accordance with known effects and safety of GH replacement for up to 86 weeks of treatment. Somapacitan may provide an effective alternative to daily GH in AGHD.
PMID: 32022863 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - February 4, 2020 Category: Endocrinology Authors: Johannsson G, Gordon MB, Rasmussen MH, Holme Håkonsson I, Karges W, Sværke C, Tahara S, Takano K, Biller BMK Tags: J Clin Endocrinol Metab Source Type: research